Scientists have discovered new information about a molecule which is part of the body’s tissue repair system. This finding could help treat non-healing wounds and injuries, such as diabetic foot.
The first patient was treated in the CONTROL hypertension (HTN)-2 clinical study, the Rox Medical’s pivotal study to evaluate the safety and effectiveness of the Rox Coupler used to create an arteriovenous anastomosis in the iliac vessels, in patients with high blood pressure.
PQ Bypass has received conditional approval of its investigational device exemption (IDE) from the US Food and Drug Administration (FDA) to initiate the pivotal DETOUR II clinical trial. As the first-ever pivotal trial for percutaneous femoropopliteal bypass, DETOUR II will evaluate the safety and effectiveness of the DETOUR System in up to 292 patients with lower limb ischaemia due to long blockages (>15cm) in the superficial femoral artery (SFA) caused by peripheral artery disease (PAD).
BTG today announces it has acquired Roxwood Medical, an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease.
Boston Scientific has announced the three-year results from the MAJESTIC trial for the Eluvia paclitaxel-eluting vascular stent system at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), in Copenhagen, Denmark.
The six-month results from the full clinical cohort of the EffPAC randomised study were presented in the drug-coated balloon (DCB) abstracts session at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2017 conference in Copenhagen, Denmark. The data demonstrate the efficacy of iVascular’s Luminor DCB in patients with peripheral arterial disease (PAD).
The European results of the first-in-human trial of Vascular Dynamics’ MobiusHD implant indicate that the device is associated with a reduction in 24-hour ambulatory systolic blood pressure of 21mmHg from baseline at six months after implantation in patients with resistant hypertension. The study was presented at the European Society of Cardiology (ESC) congress (26–30 August, Barcelona, Spain) and published in The Lancet.
Deep venous stenting has become increasingly used to treat patients with pathological obstruction of venous return in the femoro-iliocaval venous segment following the development of new dedicated venous stents. Patients treated range from those with an isolated non-thrombotic iliac vein lesion, to those with extensive post-thrombotic disease requiring extensive reconstruction. In this commentary article, Adam Gwozdz writes that the challenges when treating these different groups of patient can vary and the postoperative anticoagulation management often requires personalisation.
More than 25% of the adult population is affected by varicose veins, with more than a 15% prevalence of chronic venous insufficiency (C3–C6), which induces a considerable burden on the health of these patients. The Bonn Vein Study found that 21% of the adult population had venous reflux >0.5s. For several reasons, such as low awareness, difficulty in diagnosing, and lack of recognition of the disabling nature of this disease, the severity of the health problems caused by chronic venous disease is poorly acknowledged, and it has received, until now, little recognition from public health care systems, which focus their attention on lifethreatening conditions, Armando Mansilha writes.
Leg ulceration is the poor relation of vascular disease, yet, as Sophie Renton writes, it is a very common problem. It is estimated that 1/1,000 people in the UK will have a leg ulcer at some stage in their lives. Leg ulcers become more common with ageing and by age 80 and above, approximately 20/1,000 people will have a leg ulcer. Renton presented on the new guidelines at the Venous Forum held at the Royal College of Medicine in London from 11–12 July.
Coming from a non-medical background, Keith Poskitt is unable to pinpoint exactly how his interest in the field developed. At school, science and sports—rugby and cricket in particular—vied for his attention. Following a serious ankle injury at the age of 19, any dreams of a sporting career were dashed. Luckily for the venous field, this set Poskitt firmly on the medicinal career path. He spoke to Venous News about the current state of venous medicine, what future developments he is keeping tabs on, and the important personal and professional lessons he has learned over the course of his varied and influential career.
Marianne De Maeseneer already wanted to become a doctor by the age of 12, with her imagination captured by the idea of working in developing countries. A “series of coincidences” led her towards vascular and venous medicine, in which she decided to make a career. De Maeseneer spoke to Venous News about her journey to become a venous specialist, and shares some of the most notable experiences and lessons taken from her varied career.
Nick Morrison chose venous medicine as he wanted a challenging career. Although he initially worried that he would become bored working in the venous field, his long and distinguished career since then is proof of the complexity and depth of the venous and endovenous space. Morrison spoke to Venous News about his current research interests and professional goals, his volunteer medical organisation, and the advice he would give to young physicians embarking on a career in venous and endovenous medicine.
Continuing work to develop an improved percutaneous valvuloplasty procedure “is promising”, said Johann Chris Ragg (Angioclinic Vein Centers, Berlin, Munich, Germany, and Zurich, Switzerland), as he updated delegates on the technique at the annual American College of Phlebology meeting (ACP; 2–5 November, Austin, USA). He also argued that now is the time to “prepare the stage” for this treatment, primarily by recognising early phase reflux as its own specific disease.
ManaMed has introduced PlasmaFlow, the first US Food and Drug Administrator-approved portable and tubeless deep vein thrombosis (DVT) prevention device throughout the USA.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos